Clinical journal of oncology nursing · 2024
Administration of Goserelin at Alternative Injection Sites for Premenopausal Breast Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Аннотация
BACKGROUND: The standard of care for hormone receptor-positive breast cancer often involves prolonged use of ovarian function suppression (OFS) therapies, including goserelin. Manufacturer recommendations instruct nurses to inject goserelin subcutaneously into the anterior abdominal wall, below the navel line. However, certain patients may be inclined to avoid abdominal injections because of their surgical histories or personal preferences.
OBJECTIVES: This study examines the patient outcomes for goserelin injections at alternative injection sites (AISs) in premenopausal patients with estrogen receptor-positive breast cancer.
METHODS: A retrospective chart review was conducted to identify premenopausal women with estrogen receptor-positive breast cancer who received goserelin at an AIS. Absence of menses was a surrogate marker estimating OFS performance.
FINDINGS: Of 26 patients who received goserelin at an AIS, all patients reported the absence of menses with no tolerability concerns. For patients who may want to avoid abdominal administration, injection of goserelin at an AIS appears to be a viable strategy and offers flexibility for OFS management in breast cancer.
OBJECTIVES: This study examines the patient outcomes for goserelin injections at alternative injection sites (AISs) in premenopausal patients with estrogen receptor-positive breast cancer.
METHODS: A retrospective chart review was conducted to identify premenopausal women with estrogen receptor-positive breast cancer who received goserelin at an AIS. Absence of menses was a surrogate marker estimating OFS performance.
FINDINGS: Of 26 patients who received goserelin at an AIS, all patients reported the absence of menses with no tolerability concerns. For patients who may want to avoid abdominal administration, injection of goserelin at an AIS appears to be a viable strategy and offers flexibility for OFS management in breast cancer.